title: Interleukin-1β and tumor necrosis factor-α: reliable targets for protective therapies in Parkinson's Disease?
abstract: Neuroinflammation has received increased attention as a target for putative neuroprotective therapies in Parkinson's Disease (PD). Two prototypic pro-inflammatory cytokines interleukin-1β (IL-1) and tumor necrosis factor-α (TNF) have been implicated as main effectors of the functional consequences of neuroinflammation on neurodegeneration in PD models. In this review, we describe that the functional interaction between these cytokines in the brain differs from the periphery (e.g., their expression is not induced by each other) and present data showing predominantly a toxic effect of these cytokines when expressed at high doses and for a sustained period of time in the substantia nigra pars compacta (SN). In addition, we highlight opposite evidence showing protective effects of these two main cytokines when conditions of duration, amount of expression or state of activation of the target or neighboring cells are changed. Furthermore, we discuss these results in the frame of previous disappointing results from anti-TNF-α clinical trials against Multiple Sclerosis, another neurodegenerative disease with a clear neuroinflammatory component. In conclusion, we hypothesize that the available evidence suggests that the duration and dose of IL-1β or TNF-α expression is crucial to predict their functional effect on the SN. Since these parameters are not amenable for measurement in the SN of PD patients, we call for an in-depth analysis to identify downstream mediators that could be common to the toxic (and not the protective) effects of these cytokines in the SN. This strategy could spare the possible neuroprotective effect of these cytokines operative in the patient at the time of treatment, increasing the probability of efficacy in a clinical setting. Alternatively, receptor-specific agonists or antagonists could also provide a way to circumvent undesired effects of general anti-inflammatory or specific anti-IL-1β or TNF-α therapies against PD.
authors: Institute Leloir Fundation - IIBBA-CONICET Buenos Aires, Argentina.
authors: María C
authors: MC
authors: Leal
authors: Juan C
authors: JC
authors: Casabona
authors: Mariana
authors: M
authors: Puntel
authors: Fernando J
authors: FJ
authors: Pitossi
keywords: Parkinson’s Disease; inflammation; interleukin-1β; neurodegeneration; tumor necrosis factor-α
references: J Neuroinflammation. 2008 Oct 17;5:45
references: 18925972
references: Ann Neurol. 2005 Dec;58(6):963-7
references: 16240369
references: J Biochem. 2009 Aug;146(2):167-72
references: 19386778
references: Proc Natl Acad Sci U S A. 1968 Dec;61(4):1250-5
references: 5249808
references: Brain. 2008 Jul;131(Pt 7):1880-94
references: 18504291
references: Immunol Rev. 2012 Mar;246(1):205-20
references: 22435557
references: Cell Death Differ. 2008 Apr;15(4):730-8
references: 18202703
references: J Neuroimmunol. 2008 Sep 15;201-202:227-36
references: 18692253
references: Hum Mol Genet. 2009 Apr 15;18(R1):R48-59
references: 19297401
references: Brain. 1997 Mar;120 ( Pt 3):435-44
references: 9126055
references: Epilepsy Behav. 2006 Feb;8(1):127-36
references: 16376157
references: Sci Signal. 2010 Jan 19;3(105):cm1
references: 20086235
references: J Immunol. 2007 Aug 1;179(3):1872-83
references: 17641054
references: Cell. 2009 Apr 3;137(1):47-59
references: 19345186
references: Neurobiol Dis. 2010 Mar;37(3):630-40
references: 19969084
references: J Immunol. 2000 Aug 15;165(4):2232-9
references: 10925311
references: Eur J Neurosci. 2003 Nov;18(10):2731-42
references: 14656322
references: J Neural Transm Suppl. 2000;(58):143-51
references: 11128604
references: Neurosci Lett. 2010 Aug 16;480(2):158-61
references: 20561568
references: Neurosci Lett. 1996 Jun 14;211(1):13-6
references: 8809836
references: J Neural Transm (Vienna). 2005 May;112(5):601-12
references: 15583962
references: J Neurosci. 2005 Oct 5;25(40):9275-84
references: 16207887
references: Circ Shock. 1991 Feb;33(2):84-91
references: 2049816
references: Neurosci Lett. 2000 Apr 21;284(1-2):73-6
references: 10771165
references: Curr Opin Neurol. 2002 Jun;15(3):349-54
references: 12045736
references: Neurosci Lett. 2012 Jul 26;522(1):30-5
references: 22704918
references: Neurosci Lett. 1997 Nov 28;238(1-2):65-8
references: 9464656
references: Blood. 1998 Jan 15;91(2):577-84
references: 9427712
references: J Neuroimmunol. 2005 Nov;168(1-2):96-110
references: 16112750
references: J Neuropathol Exp Neurol. 1999 Mar;58(3):245-54
references: 10197816
references: Mol Ther. 2011 Jan;19(1):46-52
references: 20959812
references: J Neuroimmunol. 2011 May;234(1-2):1-6
references: 21474190
references: J Neurochem. 2004 Apr;89(2):337-43
references: 15056277
references: Circulation. 1999 Jun 29;99(25):3224-6
references: 10385494
references: J Neuroimmunol. 2010 May;222(1-2):29-39
references: 20350768
references: EMBO J. 1990 May;9(5):1503-10
references: 2328723
references: Am J Physiol Regul Integr Comp Physiol. 2000 Jul;279(1):R93-8
references: 10896869
references: Cell Death Dis. 2012 Jul 05;3:e338
references: 22764097
references: Can J Neurol Sci. 2012 Jan;39(1):58-64
references: 22384497
references: Neuroscience. 2004;124(3):619-28
references: 14980732
references: Pharmacol Ther. 2008 Feb;117(2):244-79
references: 18155297
references: Neurosci Lett. 2002 Jun 21;326(1):67-9
references: 12052540
references: J Neuroinflammation. 2008 Feb 27;5:8
references: 18304357
references: J Invest Dermatol. 1990 Dec;95(6 Suppl):100S-104S
references: 2258624
references: Blood. 1996 Mar 15;87(6):2095-147
references: 8630372
references: J Neurosci Res. 1997 May 15;48(4):287-98
references: 9169855
references: Am J Pathol. 2004 Nov;165(5):1827-37
references: 15509551
references: FASEB J. 2006 Apr;20(6):670-82
references: 16581975
references: Eur J Neurosci. 2005 Sep;22(5):1158-68
references: 16176358
references: Oxid Med Cell Longev. 2010 Jul-Aug;3(4):283-7
references: 20972375
references: Am J Epidemiol. 2008 Jan 1;167(1):90-5
references: 17890755
references: Nat Rev Neurol. 2012 Aug;8(8):435-42
references: 22777251
references: J Neurochem. 2004 May;89(4):822-33
references: 15140182
references: Brain Res. 2007 May 25;1147:240-7
references: 17346684
references: Physiol Rev. 1999 Jan;79(1):1-71
references: 9922367
references: FASEB J. 2002 Sep;16(11):1474-6
references: 12205053
references: J Neurosci. 2000 Jan 1;20(1):149-55
references: 10627591
references: Brain Res Dev Brain Res. 2002 Jan 31;133(1):27-35
references: 11850061
references: J Neurol. 2008 Feb;255(2):301-2
references: 17994309
references: N Engl J Med. 2012 Oct 18;367(16):1529-38
references: 23075179
references: FASEB J. 2005 Mar;19(3):452-4
references: 15629887
references: Neurosci Lett. 2000 Aug 11;289(3):165-8
references: 10961655
references: J Neurochem. 2003 May;85(3):651-61
references: 12694391
references: Eur J Immunol. 2008 Mar;38(3):720-31
references: 18266271
references: J Neuroimmunol. 2001 Oct 1;119(2):239-47
references: 11585627
references: Life Sci. 1998;63(21):1939-52
references: 9825772
references: Nat Rev Neurol. 2010 Apr;6(4):193-201
references: 20234358
references: PLoS One. 2012;7(11):e49771
references: 23166766
references: Neurobiol Dis. 2006 Oct;24(1):183-93
references: 16901708
references: FEBS J. 2011 Apr;278(6):888-98
references: 21232019
references: Neurosci Lett. 2005 Sep 23;386(1):40-5
references: 16024175
references: J Biol Chem. 1998 Oct 23;273(43):28355-9
references: 9774460
references: Nature. 2002 Dec 19-26;420(6917):853-9
references: 12490958
references: Pharmacol Ther. 1999 Mar;81(3):163-221
references: 10334661
references: Brain Struct Funct. 2014 Jan;219(1):151-70
references: 23262920
references: Nat Med. 2010 Jun;16(6):653-61
references: 20495568
references: Ann Neurol. 2012 Jan;71(1):76-83
references: 22275254
references: Neurosci Biobehav Rev. 2005 May;29(3):493-500
references: 15820552
references: J Neuropathol Exp Neurol. 2005 Sep;64(9):743-53
references: 16141783
references: J Neurosci. 2004 Feb 25;24(8):1865-72
references: 14985426
references: Parkinsonism Relat Disord. 2005 Nov;11(7):435-9
references: 16154791
references: Exp Neurol. 2012 Oct;237(2):267-73
references: 22819262
references: Neurosci Lett. 1994 Oct 24;180(2):147-50
references: 7700568
references: Respir Res. 2005 Nov 14;6:136
references: 16285886
references: Exp Neurol. 2002 Sep;177(1):183-92
references: 12429221
references: ScientificWorldJournal. 2012;2012:756357
references: 22566778
references: Epilepsia. 1994 May-Jun;35(3):616-26
references: 8026408
references: Parkinsons Dis. 2011;2011:931572
references: 21687774
references: Blood. 2011 Apr 7;117(14):3720-32
references: 21304099
references: Trends Immunol. 2011 Mar;32(3):110-6
references: 21333600
references: J Neurochem. 2002 Apr;81(1):150-7
references: 12067227
references: Neurol Sci. 2011 Feb;32(1):31-4
references: 20532580
references: Arch Neurol. 2007 Jun;64(6):836-40
references: 17562931
references: Cell. 1993 May 7;73(3):431-45
references: 8387891
references: Gene Ther. 2003 Jun;10(11):946-54
references: 12756415
references: J Neurosci. 1999 May 1;19(9):3440-7
references: 10212304
references: Eur J Epidemiol. 2011 Jun;26 Suppl 1:S1-58
references: 21626386
references: J Neurosci. 2006 Sep 13;26(37):9365-75
references: 16971520
references: Exp Neurol. 2001 Jun;169(2):219-30
references: 11358437
references: Proc Natl Acad Sci U S A. 2012 Jul 24;109(30):12189-94
references: 22778412
references: Viral Immunol. 2005;18(1):41-78
references: 15802953
references: Eur J Neurosci. 2007 Jul;26(1):79-89
references: 17581257
references: CNS Drugs. 2009 Sep;23(9):713-25
references: 19689163
references: Am J Pathol. 2005 Dec;167(6):1677-87
references: 16314479
references: Neurotherapeutics. 2010 Oct;7(4):413-23
references: 20880505
references: Mov Disord. 2002 Jan;17(1):116-24
references: 11835448
references: Neurosci Lett. 2005 Feb 28;375(2):107-11
references: 15670651
references: J Immunol. 2005 Apr 15;174(8):4852-9
references: 15814712
references: Curr Pharm Des. 2005;11(8):999-1016
references: 15777250
references: Neurosci Lett. 1994 May 19;172(1-2):151-4
references: 8084523
references: J Neurol Neurosurg Psychiatry. 2003 Jun;74(6):788-9
references: 12754353
references: Exp Neurol. 2011 Feb;227(2):237-51
references: 21093436
references: J Neuroinflammation. 2008 May 29;5:23
references: 18510752
references: Brain Res. 2002 Dec 20;958(1):89-99
references: 12468033
references: Front Biosci. 2003 Sep 01;8:s826-37
references: 12957870
references: Nat Neurosci. 2001 Nov;4(11):1116-22
references: 11600888
references: J Neurol Sci. 1973 Dec;20(4):415-55
references: 4272516
references: Proc Natl Acad Sci U S A. 2006 Aug 15;103(33):12481-6
references: 16885212
references: J Neurosci. 2011 Dec 7;31(49):18048-59
references: 22159118
references: Rheum Dis Clin North Am. 1998 Aug;24(3):579-91
references: 9710888
references: Surg Oncol. 2006 Jul;15(1):25-8
references: 16814541
references: Acta Neurol Scand. 2011 Sep;124(3):176-81
references: 20880267
references: Agents Actions Suppl. 1991;35:51-7
references: 1664189
references: Biochemistry. 2008 Sep 16;47(37):9911-9
references: 18707126
references: Nat Rev Immunol. 2005 Aug;5(8):629-40
references: 16034365
references: Science. 1985 Nov 8;230(4726):630-2
references: 2413547
references: Eur J Immunol. 2006 Oct;36(10):2768-80
references: 16983719